Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Elderly chronic hepatitis C patients benefit from DAAs

06 Nov 2019

Direct-acting antivirals (DAAs) are effective for chronic hepatitis C even in elderly adults, resulting in respectable rates sustained virological response (SVR) independently of age, a recent study has shown.

Researchers retrospectively examined 1,151 elderly chronic hepatitis C patients who were further disaggregated according to age: 65 years (mean age, 70.85±5.47 years; 59.1 percent male) and <65 years (mean age, 54.06±9.37 years; 62.4 percent male). Comparative DAA efficacy was the primary outcome.

The treatment response rate in the overall cohort was 97.7 percent. This was slightly higher in the younger subgroup (98.3 percent vs 97.1 percent), though the difference was not statistically significant. Twenty-six patients failed treatment; 15 belonged to the older group.

SVR rates 12 weeks after treatment (SVR12) were 97.4 percent, 97.2 percent and 86.7 percent for the 65–74-years, 75–84-years and 85-years age groups, respectively. No between- and among-group differences were reported.

Multivariate logistic regression analysis revealed that the combination of DAAs received (p0.001) and coinfection with HIV (p=0.001) were the only significant predictors of SVR12. Both factors were also initially predictive of treatment response in the older subgroup, though their respective significance were attenuated upon multivariable analysis.

Other variables, such as comorbidities, fibrosis stage, baseline viral load, previous treatment history and demographic factors, were all unrelated to the likelihood of treatment response.

“Treatment should not be withheld purely on the grounds of advanced age, and older age should not be a barrier to [hepatitis C virus] treatment,” said researchers. “Older adults should have the opportunity to benefit from the high cure rates and health benefits associated with viral eradication.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.